Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients

Medical Oncology

Volumn 17, Issue 3, 2000, Pages 203-210

  Ladetto, M ^a   Bergui, L ^a   Ricca, I ^a   Campana, S ^a   Pileri, A ^a   Tarella, C ^a  

^a Cattedra di Ematologia   (Italy)

Author keywords

Chronic lymphocytic leukaemia; Monoclonal antibodies; Rituximab

Indexed keywords

CD20 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FLUDARABINE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CHILL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; LYMPHOCYTE COUNT; MALE; NAUSEA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

EID: 0033837234     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02780529     Document Type: Article

References (34)

1. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent
2. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia The French Cooperative Group on CLL
3. Present status of purine analogs in the therapy of chronic lymphocytic leukemias
4. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
5. Chronic lymphocytic leukemia in the next decade: Where do we go from here?
6. Chronic lymphocytic leukemia: From palliative therapy to curative intent
7. Fludarabine treatment in B-cell chronic lymphocytic leukemia: Response, toxicity and survival analysis in 47 cases
8. Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections
9. The infectious complications of chronic lymphocytic leukemia
10. Monoclonal antibody therapy for indolent lymphomas
11. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
12. IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma
13. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia
14. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia
15. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
16. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study
17. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma
18. Future strategies toward the cure of indolent B-cell malignancies. New biologic therapies
19. Campath 1H therapy in 29 patients with refractory C.L.L.: 'True' complete remission is an attainable goal
20. Preclinical and phase I and II trials of rituximab
21. Immunosuppressive toxicity of CAMPATH-1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma
22. Campath-1H in the treatment of T prolymphocytic leukemia (T PLL)
23. Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine
24. IDEC-C2B8 anti-CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: Evaluation of response on 48 patients
25. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)
26. Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
27. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody. (IDEC-C2B8, rituximab)
28. Rituximab therapy in hematologic malignancy patients with circulating blood rumor cells: Association with increased infusion-related side effects and rapid blood tumor clearance
29. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia
30. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
31. Rituxan has significant activity in patients with CLL
32. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
33. In vivo purging of circulating CD34+ progenitor cells in low-grade lymphoma with Rituximab and high-dose chemotherapy
34. High-dose chemotherapy with PBPC autograft in low grade non Hodgkin's lymphoma